1.Clinical analysis on 28 patients with hemophagocytic lymphohistiocytosis syndrome.
Mi-Mi SHU ; Hua-Feng ZHU ; Tao ZHANG ; Guang-Xun GAO ; Xie-Qun CHEN
Journal of Experimental Hematology 2010;18(2):463-465
In order to profoundly understand the clinical and laboratorial characteristics and inducing factors of hemophagocytic lymphohistiocytosis syndrome (HLH), 28 HLH patients received from 2004 to 2009 years in our hospital were analyzed retrospectively. The results indicated that all of the patients had a history with prolonged fever (more than 1 week), pancytopenia, hepatosplenomegaly, elevated ferritin level, hypofibrinogen, and hemophagocytosis in bone marrow. HLH was the first characteristic sign of malignant lymphoma in 9 patients; 1 patient had a clinical manifestation similar to fulminant hepatic failure; severe psycho-abnormality occurred in 1 HLH patient and pronounced hemophagocytosis were detected in his cerebrospinal fluid; 1 patient was eventually diagnosed as having HLH by the findings in a lymph node biopsy showing obvious hemophagocytosis. Additionally, the analysis of underlying factors in 28 patients with HLH indicated 11 patients with EB virus-associated HLH, 11 with lymphoma-associated HLH, 2 with Leishmania-associated HLH, and 3 with autoimmune disease-associated HLH. It is concluded that HLH disease is characterised with high heterogenicity in both clinical features and inducing factors; in addition, the patients from a pasturing area should be paid attention to parasite infection such as leishmania.
Adolescent
;
Adult
;
Aged
;
Autoimmune Diseases
;
complications
;
Child
;
Child, Preschool
;
Female
;
Herpesvirus 4, Human
;
isolation & purification
;
Humans
;
Leishmania
;
isolation & purification
;
Lymphohistiocytosis, Hemophagocytic
;
complications
;
diagnosis
;
parasitology
;
virology
;
Male
;
Middle Aged
;
Retrospective Studies
;
Young Adult
2.Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line.
Bo LIU ; Qing-Xian BAI ; Xie-Qun CHEN ; Guang-Xun GAO ; Hong-Tao GU
Journal of Experimental Hematology 2007;15(4):762-766
To explore the mechanisms of suppression growth and induction apoptosis of curcumin on human multiple myeloma cell line RPMI8226, the suppressive effect of curcumin on RPMI8226 was examined by MTT assay; the induction apoptosis and cell cycle arrest of curcumin on RPMI8226 were determined by flow cytometry (FCM); the changes of survivin, Bcl-2, Bax mRNA levels were detected by RT-PCR. The results showed that curcumin obviously suppressed the proliferation of RPMI8226 in both time- and dose-dependent manners, and the IC(50) were 12.15 micromol/L, 4.9 micromol/L for 24 and 48 hours respectively. FCM indicated that the apoptosis ratio rose from 10.6% of untreated cells up to 36.9% of treated cells (p < 0.05), and curcumin arrested cell cycle of RPMI8226 at G(2)/M phase. RT-PCR showed that RPMI8226 cells expressed survivin, Bcl-2 strongly and Bax slightly; while RPMI8226 cells were treated with curcumin 10 micromol/L for 24 hours, the expressions of survivin, Bcl-2 mRNA were apparently down-regulated, and the expression of Bax mRNA was markedly up-regulated. It is concluded that curcumin can suppress the proliferation of human multiple myeloma cell line RPMI8226, and induce their apoptosis. The mechanism of antitumous effect of curcumin may be related to down-regulation of survivin, Bcl-2 mRNA and up-regulation of Bax mRNA.
Antineoplastic Agents
;
pharmacology
;
Apoptosis
;
drug effects
;
Cell Line, Tumor
;
Cell Proliferation
;
drug effects
;
Curcumin
;
pharmacology
;
Humans
;
Inhibitor of Apoptosis Proteins
;
Microtubule-Associated Proteins
;
metabolism
;
Multiple Myeloma
;
metabolism
;
pathology
;
Proto-Oncogene Proteins c-bcl-2
;
metabolism
;
RNA, Messenger
;
metabolism
3.Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells.
Yang YANG ; Hong-Juan DONG ; Guang-Xun GAO ; Yi-Wei WANG ; Hong-Tao GU ; Xie-Qun CHEN
Journal of Experimental Hematology 2012;20(2):335-338
This study was purposed to investigate the effect of triptolide on bortezomib-induced apoptosis in multiple myeloma cell line NCI-H929(H929). MTT assay was applied to detect the inhibitory effects of triptolide and bortezomib alone or combined at different concentrations on H929 cells, the cell apoptosis was assayed by flow cytometry with Annexin V-FITC/PI staining. The results showed that both triptolide (10 - 100 ng/ml) and bortezomib (10 - 100 nmol/L) alone or combination inhibited the proliferation of MM cell line H929 in a concentration-dependent manner. The apoptotic rate of H929 cells in group of triptolide combined with bortezomib was much higher than that in groups of single drug or control; moreover, the apoptotic rate of H929 cells treated by non-inhibitory concentration of triptolide (10 ng/ml) combined with bortezomib (40 nmol/L) for 24 h was significantly higher than that by bortezomib alone (P < 0.05). It is concluded that triptolide can significantly enhance the pro-apoptotic activity of bortezomib in MM cells.
Apoptosis
;
drug effects
;
Boronic Acids
;
pharmacology
;
Bortezomib
;
Cell Line, Tumor
;
Diterpenes
;
pharmacology
;
Epoxy Compounds
;
pharmacology
;
Humans
;
Multiple Myeloma
;
pathology
;
Phenanthrenes
;
pharmacology
;
Pyrazines
;
pharmacology
4.Measurement of serum free light chains and its clinical significance in 20 newly diagnosed patients of multiple myeloma.
Xiao-Bei MAO ; Xie-Qun CHEN ; Yong-Ping ZHAI ; Rong LIANG ; Guang-Xun GAO ; Guo-Guang MA ; Ya-Ping YU ; Feng LI
Journal of Experimental Hematology 2008;16(4):829-832
The objective of this study was to explore the clinical significance of measuring serum free light chains (sFLC) and to compare with serum total light chains (free and binded) in multiple myeloma (MM). sFLC in 20 newly diagnosed MM patients and 20 cases of healthy people as control were measured by immuno-nephelometric assays; the serum light chains and kappa/lambda ratio were measured in all patients, while immunofixation electrophoresis (IFE) tests were carried out at the same time in 18 out of 20 patients. The results showed that the abnormality of serum free light chains and kappa/lambda ratio were found in all of the 20 newly diagnosed MM patients (p < 0.01). The measurement of sFLC showed higher sensitivity than the total serum chains (p < 0.01). It is concluded that the method testing sFLC by immuno-nephelometric assay combined with kappa/lambda ratio is valuable for MM diagnosis, and the measurement of sFLC can be used as one of indicators for MM diagnosis.
Adult
;
Aged
;
Biomarkers, Tumor
;
blood
;
Female
;
Humans
;
Immunoglobulin kappa-Chains
;
blood
;
Immunoglobulin lambda-Chains
;
blood
;
Male
;
Middle Aged
;
Multiple Myeloma
;
blood
5.Difference of gene expression profiles between HL-60/VCR and HL-60 cells detected by human genome genechip.
Bao-Xian DONG ; Xie-Qun CHEN ; Zhe WANG ; Rong LIANG ; Qing-Xian BAI ; Gao-Sheng HUANG ; Wei-Ping ZHANG ; Guang-Xun GAO ; Dong-Mei HAN
Journal of Experimental Hematology 2006;14(3):492-496
This study was aimed to detect the gene expression profile changes between human acute leukemia cell line HL-60 and VCR-resistance HL-60, and to investigate the underlying mechanisms of MDR by using genechip technology. In experiments, mRNA were harvested using TrizoL reagent from these two cell lines, through RT-PCR, the biotinylated nucleotide were incorporated into the cRNA during the in vitro transcription reaction. The high quality RNA was hybridized to the gene expression array--human genome U133A developed by Affymetrix. It was scanned by G2500A GeneArray Scanner and the acquired image was analysed by a series of softwares. The results showed that 5,507 genes were differentially expressed between human acute leukemia cell line HL-60 and VCR-resistant HL-60. Compared with HL-60, 3,100 genes were up-regulated and 2,407 genes were down-regulated in VCR-resistant cell line. These genes were involved in different cell activities such as growth regulation and signal transduction. Among the genes with remarkable differential expression between the two cell lines, 435 were up-regulated and 605 were down-regulated. It is concluded that many different kinds of genes are involved in the mechanism of MDR and there is an intricate molecular network that controls the sensitivity of leukemia cells to the chemotherapeutic agents. Genechip is an efficient tool for parallel gene expression analysis.
Drug Resistance, Neoplasm
;
genetics
;
Gene Expression Profiling
;
Gene Expression Regulation, Neoplastic
;
Genome, Human
;
HL-60 Cells
;
Humans
;
Oligonucleotide Array Sequence Analysis
;
Vincristine
;
pharmacology
6.CMV pp65 gene modified dendritic cells activate autologous T cells.
Guang-Xun GAO ; Xie-Qun CHEN ; Jin-Yi ZHANG ; Hua-Feng ZHU ; Bao-Xia DONG ; Hong-Tao GU ; Ying GAO ; Yao-Zhu PAN
Journal of Experimental Hematology 2008;16(2):397-400
Cytomegalovirus (CMV) infection is a dangerous complication in patients with chronic graft versus host disease (cGVHD). CMV-specific immunity depends on the activity of T cells. This study was aimed to investigate the effect of CMV pp65 gene modified dendritic cells (DCs) on activation of autologous T cells. Lentivirus system was utilized to introduce the CMV full-length pp65 gene into mouse DCs; CpG-DNA was used to induce mature DCs; flow cytometry and immunofluorescence were used to determine the expression of antigen and IFNgamma in T lymphocytes. The results showed that the DCs were infected with lentivirus at a multiplicity of infection (MOI) of 50 with optimal infectious efficiency of 30%-40%; mature DCs expressing pp65 gene could stimulate autologous naive T cells to express CD69 specifically; mature DCs expressing PP65 could stimulate autologous CD4+ or CD8+ T cells to produce IFNgamma. It is concluded that CMV pp65-modified and CpG-DNA-induced mature DCs can activate CMV-specific T lymphocytes in vitro.
Animals
;
Antigens, CD
;
genetics
;
metabolism
;
Antigens, Differentiation, T-Lymphocyte
;
genetics
;
metabolism
;
Antigens, Viral
;
immunology
;
CD4-Positive T-Lymphocytes
;
immunology
;
CD8-Positive T-Lymphocytes
;
immunology
;
CpG Islands
;
genetics
;
Cytomegalovirus
;
immunology
;
DNA
;
genetics
;
Dendritic Cells
;
cytology
;
immunology
;
metabolism
;
Humans
;
Interferon-gamma
;
genetics
;
metabolism
;
Lectins, C-Type
;
Lentivirus
;
genetics
;
metabolism
;
Mice
;
Phosphoproteins
;
genetics
;
metabolism
;
Viral Matrix Proteins
;
genetics
;
metabolism
7.PI3-kinase mediates thrombin-induced platelet aggregation through mDia1 pathway..
Guang-Xun GAO ; Hong-Juan DONG ; Hong-Tao GU ; Ying GAO ; Yao-Zhu PAN ; Yi-Wei WANG ; Yang YANG ; Xie-Qun CHEN
Chinese Journal of Hematology 2010;31(3):176-180
OBJECTIVETo investigate the expression of mDia1 (mammalian diaphanous 1)in platelet and the role of mDia1 or phosphatidylinositol 3-kinase (PI3K) in the process of thrombin-induced platelet aggregation.
METHODSThe extent of platelet aggregation was measured by a platelet aggregation system and the expression of mDia1 and its relation with F-actin in quiescent, spreading or aggregated platelets by Western blot.
RESULTSThere was no significant difference in mDia1 expression level between quiescent and activated platelets. mDia1 moved from a Triton-X100-soluble cytosolic fraction to insoluble cytoskeleton fraction after thrombin induced platelets aggregation. Anti-mDia1 antibody could inhibit this aggregation. PI3K inhibitor Wortmannin or Ly294002 inhibited the thrombin induced platelet aggregation and the above mentioned mDia1 translocation.
CONCLUSIONPI3-kinase mediates the thrombin-induced platelet aggregation through mDia1 pathway.
Actins ; Animals ; Blood Platelets ; metabolism ; Humans ; Phosphatidylinositol 3-Kinases ; Platelet Aggregation ; Platelet Aggregation Inhibitors ; pharmacology ; Thrombin ; pharmacology
8.PI3-kinase mediates activity of RhoA and interaction of RhoA with mDia1 in thrombin-induced platelet aggregation.
Guang-Xun GAO ; Hong-Juan DONG ; Hong-Tao GU ; Ying GAO ; Yao-Zhu PAN ; Yang YANG ; Xie-Qun CHEN
Journal of Experimental Hematology 2009;17(6):1555-1559
The aim of this study was to investigate the role of RhoA/mDia1 pathway in the process of thrombin-induced platelet aggregation and regulatory effect of PI3K inhibitor on this process. The human platelets were isolated from peripheral blood, the activation of RhoA, Rac1 and Cdc42 in the platelet aggregation was detected by GST pull-down assay and immune co-precipitation, the interaction of RhoA, Rac1 and Cdc42 with mDia1 and the formation of complex in the process of platelet aggregation were determined by immune coprecipitation, and the effect of PI3K inhibitor (wortmannin) on above-mentioned process was assayed. The results showed that thrombin elevated the activity of RhoA and the binding capability of RhoA with mDia1 during thrombin-induced platelet aggregation and spreading on Fg coated coverslips. Wortmannin inhibited the rising of RhoA activity and the binding level of RhoA with mDia1 induced by thrombin. Thrombin elevated the activity of Rac1 and Cdc42 during thrombin-induced platelet aggregation, but could not induce binding of Rac1 or Cdc42 with mDia1. Wortmannin could not inhibit the rising of Rac1 and Cdc42 activity induced by thrombin. It is concluded that the PI3-kinase regulates the thrombin-induced actin cytoskeleton reconstitution in platelets by RhoA-mDia1 pathway.
Actins
;
metabolism
;
pharmacology
;
Adaptor Proteins, Signal Transducing
;
immunology
;
metabolism
;
Blood Platelets
;
metabolism
;
Cells, Cultured
;
Humans
;
Phosphatidylinositol 3-Kinases
;
pharmacology
;
Platelet Aggregation
;
drug effects
;
Thrombin
;
pharmacology
;
rac1 GTP-Binding Protein
;
metabolism
;
rhoA GTP-Binding Protein
;
metabolism
;
pharmacology
9.Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells.
Hong-Juan DONG ; Xie-Qun CHEN ; Guang-Xun GAO ; Hong-Tao GU ; Yao-Zhu PAN ; Ying GAO ; Hua-Feng ZHU
Journal of Experimental Hematology 2009;17(1):107-110
This study was aimed to explore the effect of bortezomib on the apoptosis and expression of the molecular chaperone BiP in human multiple myeloma cell line NCI-H929 (H929). After treatment of H929 cells with different concentrations of bortezomib for 24 hours, cell apoptosis was assayed by flow cytometry with Annexin V-FITC/PI staining, and the expression levels of BiP mRNA and protein were detected by RT-PCR and Western blotting analysis. The results showed that bortezomib of different concentrations (20, 40 and 80 nmol/L) induced apoptosis of H929 cells in dose-dependent manner, with apoptotic rates (15.73 +/- 0.67)%, (27.83 +/- 1.26)% and (44.17 +/- 2.25)% respectively, which were significantly higher than that in control (1.21 +/- 0.07%) (p < 0.05). Bortezomib-induced up-regulation of BiP mRNA levels was almost on a parallel with BiP protein when compared with control. Under the similar apoptosis-stimulating conditions with apoptotic rates varying from 40% to 50%, expression levels of BiP mRNA and BiP protein induced by the classical endoplasmic reticulum stressor Brefeldin A (500 ng/ml, 24 h) were almost consistent with those by bortezomib (80 nmol/L, 24 h). It is concluded that bortezomib-induced apoptosis in H929 cells correlates closely with endoplasmic reticulum stress.
Apoptosis
;
drug effects
;
Boronic Acids
;
pharmacology
;
Bortezomib
;
Cell Line, Tumor
;
Endoplasmic Reticulum
;
drug effects
;
metabolism
;
Heat-Shock Proteins
;
metabolism
;
Humans
;
Multiple Myeloma
;
metabolism
;
pathology
;
Pyrazines
;
pharmacology
;
RNA, Messenger
;
genetics
10.Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma.
Hong-tao GU ; Mi-mi SHU ; Guang-xun GAO ; Bao-xia DONG ; Rong LIANG ; Lan YANG ; Qing-xian BAI ; Tao ZHANG ; Yong-qing ZHANG ; Xie-qun CHEN
Chinese Journal of Hematology 2013;34(7):622-625
OBJECTIVETo compare the efficacy and safety of standard or reduced doses of bortezomib combined with adriamycin and dexamethasone (PAD) in patients with multiple myeloma (MM).
METHODSEighty-two newly diagnosed or refractory/relapsed patients received bortezomib [either 1.2-1.3 mg/m(2) (standard dose) or 1.0-1.1 mg/m(2) (reduced dose) on day 1, 4, 8 and 11], and adriamycin (10 mg/m(2)) plus dexamethasone (40 mg/m(2)) on day 1-4 at 3-week intervals for 1 to 6 courses. The International Myeloma Working Group Criteria were used to evaluate the response. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (Version 3.0).
RESULTSTwo courses of standard dose of PAD resulted in a similar response rate of partial and very good partial complete remissions (PR) compared with reduced dose (80.0% vs 80.8%, P=0.728). Grade III- Ⅳ neutropenia and thrombocytopenia were higher with standard dose than that with reduced doses of PAD (21.1% vs11.1%, P=0.270; 10.5% vs 6.3%, P=0.619, respectively). Grade III-Ⅳ bortezomib-induced peripheral neuropathy, herpes zoster, fatigue or abdominal distention were significantly higher with standard dose than that with reduced dose of PAD (15.8% vs 1.6%, P=0.037; 26.3% vs 6.3%, P=0.028; 36.8% vs 14.3%, P=0.046; 15.8% vs 1.6%, P=0.037, respectively).
CONCLUSIONReduced dose of PAD appears to result in a similar overall response rate, but a better tolerance and safety compared with standard dose.
Aged ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Boronic Acids ; administration & dosage ; adverse effects ; therapeutic use ; Bortezomib ; Dexamethasone ; administration & dosage ; adverse effects ; Doxorubicin ; administration & dosage ; adverse effects ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma ; drug therapy ; Pyrazines ; administration & dosage ; adverse effects ; therapeutic use ; Treatment Outcome